AAVXF:OTCMKTS
Abivax SA
139,00 USD
0,00%
(0,00) 1 d.
9. 7., 9:30:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre AAVXF…
Trh. kap.
6,74 mld.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
139,00 USD
Min. za 52 týž.
71,26 USD
Beta
3,09
Akcie v obehu
87,53 mil.
Počet zamestnancov
98
Trh. kap.
6,74 mld.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
139,00 USD
Min. za 52 týž.
71,26 USD
Beta
3,09
Akcie v obehu
87,53 mil.
Počet zamestnancov
98
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
https://www.dars.gov.et/
·
pred 1 týždňom
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending Continues - Consensus Miss Rate
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Informácie o subjekte Abivax SA
Generálny riaditeľMarc de Garidel | Hartmut J. Ehrlich
Zamestnanci98
Dátum založenia4. 12. 2013
Hlavné sídlo-
Odvetvie-
Webabivax.com